Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.64 USD

11.64
2,488,853

+0.10 (0.87%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $11.59 -0.05 (-0.43%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IOVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 280 472 504 629 307
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 10 0 0 0 0
Other Current Assets 17 7 4 7 9
Total Current Assets 308 479 508 636 316
Net Property & Equipment 114 105 101 59 9
Investments & Advances 0 0 92 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 229 0 0 0 0
Deposits & Other Assets 67 7 8 18 9
Total Assets 780 664 777 768 345
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 33 27 27 14 16
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 69 52 57 35 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 110 91 89 55 39
Mortgages 0 0 0 0 0
Deferred Taxes/Income 17 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 1 1 1 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 12 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 196 164 156 112 46
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,594 2,069 1,795 1,487 869
Retained Earnings -2,012 -1,568 -1,172 -830 -571
Other Equity 3 -1 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 585 500 622 657 299
Total Liabilities & Shareholder's Equity 780 664 777 768 345
Total Common Equity 585 500 622 657 299
Shares Outstanding 255.90 187.80 156.90 146.60 126.20
Book Value Per Share 2.28 2.66 3.96 4.48 2.37

Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 280 361 251 626
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 10 9 10 0
Other Current Assets NA 17 12 14 11
Total Current Assets NA 308 383 275 638
Net Property & Equipment NA 114 113 113 110
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 229 224 236 0
Deposits & Other Assets NA 67 67 67 7
Total Assets NA 780 852 757 825
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 33 19 31 32
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 69 61 47 43
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 110 91 89 87
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 17 18 20 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1 1 1 1
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 196 178 179 158
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,594 2,579 2,360 2,343
Retained Earnings NA -2,012 -1,896 -1,782 -1,676
Other Equity NA 3 -9 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 585 674 579 667
Total Liabilities & Shareholder's Equity NA 780 852 757 825
Total Common Equity 0 585 674 579 667
Shares Outstanding 279.30 255.90 255.90 247.40 224.30
Book Value Per Share 0.00 2.28 2.63 2.34 2.97